Higher EU Health Spending As Expectations Expand

6 October 1996

Higher health care expectations and new medical technologies are pushing European Union health care spending upwards both as a percentage of Gross Domestic Product and in absolute terms, according to data released by the EU.

Spending per head of population in terms of purchasing power standards (PPSs), which reflect the real purchasing power of a currency in the country concerned, is 1,937 in Luxembourg, 1,695 in Germany and 1,688 in France. These countries spend almost 1.5 times more per head than the EU average, some twice as much as Spain (892), Ireland (835) or Portugal (783) and around four times more than Greece.

In 1993, the latest year for which data are available, the EU member states spent between 6% and 10% of their GDP on health care. France and Austria spent more than 9%, while Greece and Denmark spent under 7%. Between 1985 and 1993, 11 of the member states spent an increasing proportion of their GDP on health.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight